Effects of treatment of coronavirus disease 2019 with convalescent plasma in 25 B-cell–depleted patients
A Gharbharan, CH GeurtsvanKessel… - Clinical Infectious …, 2022 - academic.oup.com
A Gharbharan, CH GeurtsvanKessel, CCE Jordans, M Blaauw, M van der Klift, RJ Hassing…
Clinical Infectious Diseases, 2022•academic.oup.comTwenty-five B-cell–depleted patients (24 following anti-CD19/20 therapy) diagnosed with
coronavirus disease 2019 had been symptomatic for a median of 26 days but remained
antibody negative. All were treated with convalescent plasma with high neutralizing antibody
titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy
in this particular population.
coronavirus disease 2019 had been symptomatic for a median of 26 days but remained
antibody negative. All were treated with convalescent plasma with high neutralizing antibody
titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy
in this particular population.
Abstract
Twenty-five B-cell–depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.
Oxford University Press